Corrigendum: SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma (Oncogene (2015) 34 (5252-5263) DOI: 10.1038/onc.2014.445);SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma

Oncogene

Volumn 34, Issue 41, 2015, Pages 5252-5263

  Fan, L C ^a   Shiau, C W ^b   Tai, W T ^a   Hung, M H ^b,c   Chu, P Y ^d,e   Hsieh, F S ^a   Lin, H ^a   Yu, H C ^a   Chen, K F ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^e FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FIBRONECTIN; NERVE CELL ADHESION MOLECULE; PROTEIN TYROSINE PHOSPHATASE SHP 1; SC 43; SORAFENIB; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; PTPN6 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; ENZYME ACTIVE SITE; EPITHELIAL MESENCHYMAL TRANSITION; GENE INACTIVATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; LIVER CELL CARCINOMA; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METASTASIS INHIBITION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN DEPLETION; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSCRIPTION INITIATION; ANIMAL; CANCER TRANSPLANTATION; ENZYMOLOGY; LIVER TUMOR; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SECONDARY; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; STAT3 TRANSCRIPTION FACTOR;

EID: 84943663583     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2017.251     Document Type: Erratum

References (34)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764-5774.
3. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-129.
4. Padua D, Massague J. Roles of TGFbeta in metastasis. Cell Res 2009; 19: 89-102.
5. Banville D, Stocco R, Shen SH. Human protein tyrosine phosphatase 1C (PTPN6) gene structure: alternate promoter usage and exon skipping generate multiple transcripts. Genomics 1995; 27: 165-173.
6. Mok SC, Kwok TT, Berkowitz RS, Barrett AJ, Tsui FW. Overexpression of the protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial ovarian cancer. Gynecol Oncol 1995; 57: 299-303.
7. Tsui HW, Hasselblatt K, Martin A, Mok SC, Tsui FW. Molecular mechanisms underlying SHP-1 gene expression. Eur J Biochem 2002; 269: 3057-3064.
8. Lopez-Ruiz P, Rodriguez-Ubreva J, Cariaga AE, Cortes MA, Colas B. SHP-1 in cell-cycle regulation. Anticancer Agents Med Chem 2011; 11: 89-98.
9. Witkiewicz A, Raghunath P, Wasik A, Junkins-Hopkins JM, Jones D, Zhang Q et al. Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma. Hum Pathol 2007; 38: 462-467.
10. Wu C, Guan Q, Wang Y, Zhao ZJ, Zhou GW. SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases. J Cell Biochem 2003; 90: 1026-1037.
11. Wu C, Sun M, Liu L, Zhou GW. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 2003; 306: 1-12.
12. Chen KF, Tai WT, Hsu CY, Huang JW, Liu CY, Chen PJ et al. Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity. Eur J Med Chem 2012; 55: 220-227.
13. Liu CY, Tseng LM, Su JC, Chang KC, Chu PY, Tai WT et al. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res 2013; 15: R63.
14. Tai WT, Shiau CW, Chen PJ, Chu PY, Huang HP, Liu CY et al. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. Hepatology 2014; 59: 190-201.
15. Yang Y, Pan X, Lei W, Wang J, Shi J, Li F et al. Regulation of transforming growth factor-beta 1-induced apoptosis and epithelial-to-mesenchymal transition by protein kinase A and signal transducers and activators of transcription 3. Cancer Res 2006; 66: 8617-8624.
16. Luo F, Xu Y, Ling M, Zhao Y, Xu W, Liang X et al. Arsenite evokes IL-6 secretion, autocrine regulation of STAT3 signaling, and miR-21 expression, processes involved in the EMT and malignant transformation of human bronchial epithelial cells. Toxicol Appl Pharmacol 2013; 273: 27-34.
17. Rokavec M, Oner MG, Li H, Jackstadt R, Jiang L, Lodygin D et al. IL-6R/STAT3/ miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest 2014; 124: 1853-1867.
18. Xiong H, Hong J, Du W, Lin YW, Ren LL, Wang YC et al. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelialmesenchymal transition. J Biol Chem 2012; 287: 5819-5832.
19. Zhang Z, Bai Y, Li P, Zhao J, Wang Y, Sun L et al. [Relationship between activated STAT3 protein and epithelial-mesenchymal transition in papillary thyroid carcinoma]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2013; 27: 1265-1268.
20. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 2007; 67: 9066-9076.
21. Simpson D, Keating GM. Sorafenib: in hepatocellular carcinoma. Drugs 2008; 68: 251-258.
22. Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ et al. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol 2011; 55: 1041-1048.
23. Lee JH, Chiang SY, Nam D, Chung WS, Lee J, Na YS et al. Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases. Cancer Lett 2014; 345: 140-148.
24. Johnston PA, Grandis JR. Grandis, STAT3 signaling: anticancer strategies and challenges. Mol Interv 2011; 11: 18-26.
25. Sainz-Perez A, Gary-Gouy H, Gaudin F, Maarof G, Marfaing-Koka A, de Revel T et al. IL-24 induces apoptosis of chronic lymphocytic leukemia B cells engaged into the cell cycle through dephosphorylation of STAT3 and stabilization of p53 expression. J Immunol 2008; 181: 6051-6060.
26. Wendt MK, Allington TM, Schiemann WP. Mechanisms of the epithelialmesenchymal transition by TGF-beta. Future Oncol 2009; 5: 1145-1168.
27. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 2003; 4: 657-665.
28. Garcia-Marcos M, Ghosh P, Farquhar MG. GIV is a nonreceptor GEF for G alpha i with a unique motif that regulates Akt signaling. Proc Natl Acad Sci USA 2009; 106: 3178-3183.
29. Ghosh P, Beas AO, Bornheimer SJ, Garcia-Marcos M, Forry EP, Johannson C et al. A G{alpha}i-GIV molecular complex binds epidermal growth factor receptor and determines whether cells migrate or proliferate. Mol Biol Cell 2010; 21: 2338-2354.
30. Mittal Y, Pavlova Y, Garcia-Marcos M, Ghosh P. Src homology domain 2-containing protein-tyrosine phosphatase-1 (SHP-1) binds and dephosphorylates G(alpha)-interacting, vesicle-associated protein (GIV)/Girdin and attenuates the GIV-phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway. J Biol Chem 2011; 286: 32404-32415.
31. Lu H, Cao X, Zhang H, Sun G, Fan G, Chen L et al. Imbalance between MMP-2, 9 and TIMP-1 promote the invasion and metastasis of renal cell carcinoma via SKP2 signaling pathways. Tumour Biol 2014; 35: 9807-9813.
32. Kang JH, Han IH, Sung MK, Yoo H, Kim YG, Kim JS et al. Soybean saponin inhibits tumor cell metastasis by modulating expressions of MMP-2, MMP-9 and TIMP- 2. Cancer Lett 2008; 261: 84-92.
33. Oh J, Seo DW, Diaz T, Wei B, Ward Y, Ray JM et al. Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res 2004; 64: 9062-9069.
34. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-395.